

**Grifols IVIG Flebogamma Is Now Available**



Flebogamma 5% (immune globulin I.V. [human]) from Instituto Grifols is now available in the United States. The drug is indicated for replacement therapy in primary (inherited) humoral immune deficiency disorders. Flebogamma is especially useful when rapid replacement of immunoglobulin G or the attainment of high serum levels of immunoglobulin G is desired.

Flebogamma is available in liquid form, which is ready for use. The drug is the most commonly used IVIG in the European market, according to a statement from Grifols.

For more information, visit [www.grifols.com](http://www.grifols.com).

**Alimta-Cisplatin Regimen Available for Malignant Pleural Mesothelioma**



Alimta (pemetrexed) plus cisplatin is the first and only drug regimen proven to help patients with malignant pleural mesothelioma live longer.

Alimta, which is marketed by Lilly, is approved for use with cisplatin for the treatment of malignant pleural mesothelioma in patients who are not candidates for surgery.

In a clinical trial involving 448 patients, those treated with Alimta plus cisplatin showed significantly greater survival times than did patients who received cisplatin alone (12.1 vs. 9.3 months). In addition, the combination was associated with a significantly greater one-year survival rate compared with cisplatin alone (50.3% vs. 38.0%).

For more information, visit [www.alimta.com](http://www.alimta.com)

**Web Site for Pharmacy Fluid Handling**

Baxa Corporation has launched a new Web site ([www.baxa.com](http://www.baxa.com)) designed to provide key information on fluid-handling products and best practices for hospital and alternate-site pharmacies. The new site includes product information with



downloadable policy and procedure guidelines and data sheets.

The site also offers technical papers, case studies and research studies on topics of pharmacy interest.

**CME Zone.com**  
Explore The Zone™